Background: Triple-negative breast cancers lack expression of estrogen and progesterone receptors and overexpression of human epidermal growth factor receptor 2 (HER2). Unlike other subgroups of patients with breast cancer, targeted therapy is currently unavailable for these patients. The aim of this study was to investigate v-src sarcoma viral oncogene homolog (Src) as a potential target for the treatment of triple-negative breast cancer.
introduction Triple-negative breast cancers are so-called as they lack expression of estrogen receptor (ER) and progesterone receptor (PR) and exhibit neither overexpression nor amplification of the human epidermal growth factor receptor 2 (HER2) gene (for review, see [1] ). Approximately 15% of invasive breast cancers are triple negative. Unlike other subgroups of patients with breast cancer, a proven targeted therapy is currently unavailable for these patients. Consequently, the only systemic therapy for triple-negative patients is cytotoxic chemotherapy.
Among the most successful new targeted therapies that have become available for cancer in recent years are agents that inhibit protein kinases, especially tyrosine kinases [2] . A specific tyrosine kinase currently undergoing active investigation as a potential new target for the treatment of multiple cancer types is v-src sarcoma viral oncogene homolog (Src) [3] [4] [5] . Src is a proto-oncogene involved in signalling that culminates in the control of multiple biological functions such as cell proliferation, cell differentiation, migration, angiogenesis and survival. Src is thus thought to play a key role in tumour formation and progression [3] [4] [5] .
Dasatinib is an orally available tyrosine kinase inhibitor that targets Src as well as related kinases such as breakpoint cluster region-Abelson oncogene (BCR-ABL), stem cell growth factor receptor and platelet-derived growth factor receptor beta. It is currently approved for the treatment of imatinib-resistant BCR-ABL-positive leukaemia [3, 4] . Previous work by Finn et al. [6] showed that triple-negative breast cell lines were particularly sensitive to dasatinib, while Huang et al. [7] reported that the subgroup of breast cancer patients expressing the dasatinib-sensitive signature included those with triplenegative tumours.
The aim of this study was to further explore Src as a potential target for the treatment of triple-negative breast cancer. In brief, we showed that Src was expressed in the majority of triple-negative breast tumours, and furthermore was present significantly more frequently in these samples compared with the non-triple-negative specimens. We also showed that dasatinib inhibits the growth of multiple triple-negative cell lines and in doing so synergises with several cytotoxic agents.
materials and methods

patient selection
Eighty-nine random triple-negative and 100 random cases of non-triplenegative patients were selected from the St Vincent's University Hospital breast cancer database. ER, PR and HER2 status were determined using standard immunohistochemistry. The antibodies used were monoclonal rabbit ER antibody (SP1; Thermo Scientific), monoclonal mouse antihuman PR (clone PgR 636; Dako Cytomation, Ireland) and anti-Her-2/neu rabbit monoclonal primary antibody (4B5; Ventana Medical Solutions Inc. Tuscon, AZ). ER and PR positivity were defined as ‡10% of cells staining positively. HER2 positivity was defined as uniform intense staining in > 30% of invasive tumour cells. Patient age and characteristics of the tumours investigated are summarised in Table 1 .
tissue microarray construction
Hematoxylin-eosin (H&E)-stained slides from each of the tumour specimens were evaluated microscopically to identify and mark suitable donor areas for the tissue microarrays (TMAs). Four 1-mm tumour tissue cores taken from the corresponding areas of each paraffin-embedded tumour blocks were then incorporated into blank recipient paraffin blocks using a manual tissue microarrayer (Beecher Instruments Inc, Sun Prairie, WI). The TMAs were inverted on glass slides and incubated at 37°C overnight. TMA blocks were sectioned at 4 lm, H&E stained and viewed microscopically. Eighty-seven (97.7%) of the triple-negative samples and 93 (93%) of the non-triple-negative samples were suitable for analysis.
immunohistochemistry Sections were initially deparaffinised by immersion in xylene, followed by immersion in industrial methylated spirits and washed in deionised water for 5 min. Antigen retrieval was carried out using 10 mM sodium citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked by applying 3% hydrogen peroxide to the sections for 10 min. For Src localisation, formalin-fixed paraffin-embedded sections were stained with a rabbit monoclonal antibody at a dilution of 1:200 (Src 36D10, Rabbit mAb #2109; Cell Signaling Technology, Beverly, MA).
The following controls were used: positive controls consisted of sections of colon and prostate adenocarcinoma and negative controls involved either incubation in phosphate-buffered saline (PBS) or with the primary antibody, mixed with excess Src antibody blocking peptide (Cell Signaling Technology). Src expression was evaluated by two independent investigators and scored for both membrane and cytoplasmic staining. Discordant cases were re-examined and a consensus was reached. Positivity was defined as ‡20% of cells staining for cytoplasmic or membrane Src. 
cells and reagents
invasion assays
Invasion and migration assays were carried out using 5 · 10 4 cells in Matrigel-coated 24-well invasion inserts for invasion assays and uncoated inserts for migration assays. Cells were seeded in reduced serum medium (5% fetal calf serum in RPMI-1640) and incubated for 6 h before dasatinib treatment, to allow cell attachment, and then treated with 100 nM dasatinib for 18 h. Cells were stained with crystal violet and the number of invading/ migrating cells was estimated by counting 10 fields of view at ·200 magnification. The average count was multiplied by the conversion factor 140 (growth area of membrane divided by field of view area, viewed at ·200 magnification) to determine the total number of invading/migrating cells. Invasion and migration assays were carried out in triplicate.
protein extraction
After 6 h of dasatinib treatment, cells were washed with ice-cold PBS and lysed in 500 ll radioimmunoprecipitation buffer containing protease inhibitors, 1 mM phenylmethylsulphonyl fluoride and 1 mM sodium orthovanadate (Sigma-Aldrich). After 20-min incubation on ice, the lysate was passed through a 21-gauge needle and centrifuged at 16 000 · g for immunoblotting Twenty to fifty micrograms of protein in sample buffer was heated to 95°C for 5 min, separated using 7.5% or 10% polyacrylamide gels (Lonza, Basel, Switzerland) and transferred to Hybond ECL nitrocellulose membrane (Amersham Biosciences, Buckinghamshire, UK). Membranes were blocked with 5% non-fat milk powder in 0.1% PBS-Tween, at room temperature for 1 h. After overnight incubation at 4°C with primary antibody in 5% blocking solution, three washes with 0.5% PBS-Tween were carried out, followed by incubation at room temperature with secondary antibody in 5% blocking solution for 1 h. Following three washes with 0.5% PBS-Tween and one PBS wash, protein bands were detected using Luminol (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Antibodies used were mouse anti-alpha-tubulin (Sigma-Aldrich), mouse anti-ephrin-A receptor 2 (EphA2) (Millipore, Billerica, MA), mouse anti-Src kinase (Millipore), rabbit anti-phospho-Src py 419 (Invitrogen, Carlsbad, CA), caveolin-1 (Millipore) and caveolin-2 (BD Biosciences, Franklin Lakes, NJ).
statistical analysis
IC 50 (concentration that causes 50% inhibition of growth) values were calculated using CalcuSyn software (Biosoft, Cambridge, UK). For combination assays, combination indices (CIs) at the ED 50 (effective dose of combination that inhibits 50% of growth) were determined using the Chou and Talalay equation [8] on CalcuSyn software (Biosoft). CI < 0.9 implies synergy, CI = 0.9-1.1 implies additivity and CI > 1.1 implies antagonism. The effects of dasatinib on invasion and migration were assessed using a two-tailed Student's t-test. For studies involving the breast cancer samples, both the Mann-Whiney U test and chi-square test (SPSS version 15.0, IBM Corp, Somers, NJ) were used. P < 0.05 were considered statistically significant.
results
Src expression in breast cancers
As shown in Table 1 , triple-negative cancers were found more frequently in women £50 years of age at diagnosis than in those > 50 years of age, in high-grade (grade 3) than in low-grade tumours (grade 1 and 2 combined) and in ductal compared with lobular tumours. Triple negativity was unrelated to tumour size, lymph node status or lymphovascular invasion. Cytoplasmic and membrane Src staining were evaluated separately. Typical staining patterns are shown in Figure 1 . Using a cut-off value of >20% of cells staining, 161 of 180 (89%) breast cancers investigated exhibited cytoplasmic staining, while 99 (55%) had membrane staining. Of the 180 samples, 98 (54%) were positive for both cytoplasmic and membrane staining, 18 (10%) were negative for both cytoplasmic and membrane staining, 63 (35%) were positive for cytoplasmic but negative for membrane but only one (0.6%) was negative for cytoplasmic and positive for membrane staining. Table 2 summarises the relationship between both cytoplasmic and membrane Src and tumour/patient characteristics. Using the chi-square test, cytoplasmic Src was detected more frequently in tumours from women £50 years at diagnosis than in women >50 years at diagnosis (P = 0.04), in high-grade (grade 3) compared with low-grade cancers (grade 1 and 2 combined) (P = 0.001) and in ductal compared with lobular cancers (P < 0.001). In contrast, cytoplasmic Src was unrelated to tumour size, lymph node status or lymphovascular invasion. Membrane Src was also detected more frequently in high-grade compared with low-grade tumours and in ductal versus lobular tumours (P < 0.001 for both). Membrane Src was unrelated to the other tumour/patient characteristic studied. original article
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The frequency of expression of cytoplasmic and membrane Src was compared in triple-negative and non-triple-negative breast cancers. Eighty three of 87 (95%) triple-negative cancers were positive for Src compared with 78 of 93 (84%) of non-triple-negative samples (P = 0.012). Similarly, membrane staining for Src was found more frequently in triple-negative than in non-triple-negative samples (74% versus 38%, P < 0.0001).
in vitro sensitivity to dasatinib Sensitivity to dasatinib was compared with two other multi-target kinase inhibitors, imatinib mesylate and sunitinib malate, which have overlapping target specificity with dasatinib (Table 3 ). All cell lines were resistant to both imatinib mesylate and sunitinib malate with IC 50 values >10 and 5 lM, respectively. The HER2 amplified cell lines were resistant to dasatinib with IC 50 values >1 lM, with the exception of the JIMT-1 cells, which showed sensitivity to dasatinib (IC 50 = 0.1 6 0.01 lM). As previously described by Finn et al. [6] , 1 lM was chosen as the cut-off for dasatinib sensitivity as serum concentrations >1 lM are unlikely to be achieved in patients [6] . Three of the five tested triple-negative breast cancer cell lines (MDA-MB-231, HCC-1143, HCC-1937) were sensitive to dasatinib (IC 50 < 1 lM). In contrast, the IC 50 values for MDA-MB-468 and BT-20 were >1 lM, which was defined as resistant based on the concentrations of dasatinib that are likely to be achievable in serum [6] . Dasatinib treatment also significantly inhibited both migration (P = 0.002) and invasion (P = 0.022) of the triple-negative MDA-MB-231 cell line (Figure 2 ).
potential biomarkers of dasatinib sensitivity
The levels of Src, phosphorylated Src and EphA2, which are targets of dasatinib, were analysed in a panel of triple-negative and HER2-amplified breast cancer cell lines ( Figure 3A) . No difference was observed in the level of Src or phosphorylated Src in dasatinib-sensitive and -resistant cells. However, EphA2 levels were significantly higher in the dasatinib-sensitive cell lines than in the resistant cells (P = 0.0385). As other investigators [6, 7] found that expression of caveolin 1 messenger RNA (mRNA) was associated with response to dasatinib, we examined caveolin 1 and 2 protein levels in our panel of cell lines. Expression of both caveolin 1 and 2 proteins was also significantly higher in dasatinib-sensitive than dasatinib-resistant breast cancer cell lines (P < 0.00002 and P < 0.0125, respectively) ( Figure 3A and B) . Following 6 h of treatment with dasatinib, levels of phosphorylated Src were significantly reduced in all cell lines, irrespective of sensitivity to dasatinib ( Figure 3C ).
preclinical evaluation of combinations of dasatinib with chemotherapy
The three dasatinib-sensitive triple-negative breast cancer cell lines (MDA-MB-231, HCC-1143, HCC1937) and one dasatinib-resistant cell line (MDA-MB-468) were treated with fixed ratio combinations of dasatinib with cisplatin, docetaxel or 5#-DFUR (Table 4) Figure S2 , available at Annals of Oncology online). In the dasatinib-resistant cell line MDA-MB-468, the combination of dasatinib with docetaxel or 5#-DFUR displayed a positive interaction, whereas the combination with cisplatin had no additive effect. CI values were not calculated for MDA-MB-468, as dasatinib did not achieve >50% inhibition at the concentrations tested.
discussion
Although Src has been previously measured in breast cancer [9, 10] , to our knowledge, this is the first study to compare its expression in triple-negative and non-triple-negative samples. In this study, we show that both cytoplasmic and membrane Src were detected in the majority of breast cancers. The frequency of detection was significantly higher in triple-negative than in non-triple-negative samples, particularly for the membrane form of Src (74% versus 38%). Previous studies have shown that inactive Src is located in the cytoplasm of cells, while active Src localises to peripheral membrane-associated focal adhesions [11, 12] . Fincham et al. [13] showed that in unstimulated NIH-3T3 cells Src staining was distributed throughout the cytoplasm, whereas in cells treated with platelet-derived growth factor, Src protein translocated to the membrane. Elsberger et al. [10] examined Src staining in 314 human breast tumours and detected cytoplasmic Src staining in 60% and membrane staining in 43% of breast tumours. They also showed that membrane staining for activated Src kinase, phosphorylated on tyrosine 419, is associated with shorter disease-specific survival, increasing grade, tumour size, ER negativity and HER2 positivity. The higher frequency of membranous Src, which we observed in the triple-negative breast tumours, may indicate higher levels of active Src in triple-negative than non-triple-negative breast tumours. Consequently, Src may be a potential target for the treatment of patients with this subtype of breast cancer. Dasatinib, an inhibitor of Src as well as related kinases, decreased proliferation in three of five triple-negative breast cancer cell lines. In contrast, only one out of four HER2-amplified cell lines was inhibited, i.e. JIMT-1 cells. Interestingly, this cell line has been classified as borderline between HER2 positive and basal like [14] , as it expresses both basal CK5/14 and luminal CK8/18 cytokeratins [15] . None of the cell lines tested displayed significant sensitivity to either imatinib or sunitinib, which suggests that sensitivity to dasatinib may be due to targeting Src and/or EphA receptors, kinases that are not inhibited by imatinib or sunitinib. Other investigators have original article Annals of Oncology also reported dasatinib sensitivity in the triple-negative cell lines investigated here [6, 7, 16, 17] . Although dasatinib inhibited proliferation in four out of the nine breast cancer lines investigated, no correlation was found between the levels of Src or phospho-Src and sensitivity. Indeed, phosphorylation of Src was reduced in all cell lines irrespective of response to dasatinib. Others have also reported a lack of correlation between Src/phosphorylated-Src levels and dasatinib growth inhibitory ability [7, [17] [18] [19] .
While the levels of Src do not appear to predict sensitivity to dasatinib, the expression levels of other genes may do so. Thus, Huang et al. [7] identified a six-gene panel that predicted sensitivity to dasatinib. These genes included EPHA2, CAV1, CAV2, ANXA1, PTRF and IGFBP2. All these genes are either targets for dasatinib or substrates for Src kinases [7] . Interestingly, expression of these genes was particularly observed in triple-negative and basal-type breast cancer cell lines [7] . Finn et al. [6] also reported an association between CAV1 mRNA expression and sensitivity dasatinib. In addition, this group found that MSN (moesin) and YAP1 (yes-associated protein-1) mRNA were predictive of response to dasatinib.
Although Huang et al. [7] detected a decrease in caveolin mRNA levels in response to dasatinib treatment, Pichot et al. [17] were unable to detect changes in caveolin protein levels following treatment of MDA-MB-231 cells with dasatinib. Rather, these investigators reported that phosphorylation of the Src family kinase substrate Crkl was decreased by dasatinib in this cell line. In ovarian cancer cell lines, Konecny et al. [20] found that high expression of EPHA2, YES, LYN CAV1, CAV2 and MSN mRNAs were associated with sensitivity to dasatinib. In agreement with previous reports showing an association between dasatinib sensitivity and high mRNA levels for EPHA2, CAV1 and CAV2 [6, 7, 20] , we found similar relationships at the protein level.
As targeted therapies are frequently administered with cytotoxic agents, we investigated the possible synergy between dasatinib and a number of these drugs. Using cell lines in culture, strong synergy was found between dasatinib and cisplatin in MDA-MB-231, HCC-1143 and HCC-1937. As far as we are aware, such synergy has not previously been reported in triple-negative breast cancer cell lines. However, Ceppi et al. [18] reported synergy between these agents in lung cancer cell lines, while Konecny et al. [20] found synergy between carboplatin and dasatinib in ovarian cancer cell lines. In our investigation, dasatinib also showed synergy in combination with docetaxel in MDA-MB-231 and HCC-1937 cells and in combination with 5#-DFUR in MDA-MB-231 and HCC-1143 cells. Synergy was previously found between dasatinib and paclitaxel (Taxol, Bristol-Myers Squibb, NJ) in ovarian cancer cell lines [20] . Although not investigated in the present study, Pichot et al. [17] recently reported synergy between dasatinib and doxorubicin in MDA-MB-231 cells. Finally, Kopetz et al. [21] reported synergy between dasatinib and oxaliplatin in colon cancer cells. Caution however, may be necessary in using Src inhibitors to treat breast cancer. Elsberger et al. [10] showed that a specific phosphorylated form of Src, i.e. cytoplasmic Src phosphorylated on tyrosine 215, was associated with good outcome in patients with breast cancer, especially in those with ER-negative disease. If phosphorylation of Y215-Src is inhibited by dasatinib, it could have adverse consequences in patients whose tumours have high levels of pY215-Src [10] . Further studies will be required to confirm the association between pY215-Src and good prognosis, and to determine whether dasatinib and/or other Src targeted therapies inhibit this phosphorylated form of Src kinase.
In conclusion, we have shown that both membrane and cytoplasmic Src are detected in the majority of triple-negative breast cancers. We have also shown that dasatinib inhibits growth of several triple-negative breast cancer cells in culture, although Src expression or phosphorylation did not appear to predict dasatinib sensitivity in vitro. Importantly, in this investigation, the combination of dasatinib and cisplatin exhibited synergy in inhibiting growth. Clinical trials combining dasatinib with cisplatin may thus be warranted in patients with triple-negative breast cancer. A gene signature comprising some or all of the following EPHA2, CAV1, CAV2, ANXA1, PTRF, IGFBP2, MSN and YAP1 might be utilised for identifying patients likely to benefit from dasatinib [7] . Alternatively, the candidate predictive markers recently described by Moulder et al. [22] could be used. 
